Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

AT7687 demonstrated a favorable safety and tolerability profile with no adverse GI tolerability signals identifiedOnce-weekly dosing potential and demonstrated target engagement across the doses tested were confirmedPreclinical data from non-human primates showed additional weight loss and significant improvements in insulin sensitivity and body composition with AT7687 in combination with cagrilintideThese data further reinforce the potential of AT7687 to become a combination partner of choice f